**Inaugural World Unilateral Biportal Endoscopy Society America Meeting**

January 25, 2025

**Purpose**

The Inaugural World Unilateral Biportal Endoscopy Society America Meeting will review and discuss various basic and advanced topics in biportal spinal endoscopy by expert faculty from South Korea and the United States. Spine surgeons who are interested in learning biportal spinal endoscopy can learn the basics with didactics and discussions about the value proposition, how to get started, overcoming the learning curve, avoiding complications, as well as specific basic techniques. More advanced surgeons can learn about incorporating emerging technologies such as navigation, augmented reality, and robotics to complement biportal spinal endoscopy, as well learn about cutting-edge cervical and thoracic spine applications. Through this meeting, we aim to demonstrate the power, versatility, and applicability of the biportal endoscopic technique.

**Target Audience**

Specialties – Orthopaedic Surgery

Professions – Physician, Nurse, Nurse Practitioner, Physician Assistant, Resident Physician

**Activity Objectives**

1 Apply basic principles of biportal spinal endoscopy to surgeons interested and new to the technique.

2 Learning advanced methods and techniques for experienced surgeons who want to add to their endoscopic skills.

**Accreditation Statement**

The University of California, Irvine School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Designation Statement**

The University of California, Irvine School of Medicine designates this Live Activity for a maximum of 6.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**California Assembly Bill 1195 and 241**

This activity is in compliance with California Assembly Bill 1195 and 241, which require CME activities with patient care components to include curriculum in the subjects of cultural and linguistic competency & implicit bias. It is the intent of AB 1195 and AB 241 to encourage physicians and surgeons, CME providers in the State of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population and reduce health disparities through appropriate professional development. Please see the CME website, <https://www.meded.uci.edu/CME/> for AB 1195 and AB 241 resources.









**Faculty & Planner Disclosures**

University of California, Irvine School of Medicine Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Amy Speers, Other | Other Planning Committee Member | Nothing to disclose - 08/26/2024 |
| Maria Lampino Guerrero, Other | Activity Administrator | Nothing to disclose - 10/10/2024 |
| Don Y Park, MD | Course Director, Faculty | Paid consultant-Alphatec|Paid consultant-GS Medical|Paid consultant-Nuvasive|Paid consultant-Seaspine|Paid consultant-Globus|Paid consultant-Stryker (Any division)|Royalties or Patent Beneficiary-Alphatec|Royalties or Patent Beneficiary-Seaspine|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Amplify Surgical|Stocks or stock options, excluding diversified mutual funds-Amplify Surgical - 08/27/2024 |
| Michael Oh, MD | Other Planning Committee Member | Membership on Advisory Committees or Review Panels, Board Membership, etc.-2nd Skull|Consulting Fee-GS Medical|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Intravent Medical - 07/24/2024 |
| Samuel Cho, MD | Faculty | Consulting Fee-SIBone|Royalties or Patent Beneficiary-Globus Medical, Inc. - 08/29/2024 |
| Ji Yeon Kim, MD | Faculty | Nothing to disclose - 11/07/2024 |
| Jeong-Yoon Park, MD, PhD | Faculty | Nothing to disclose - 10/06/2024 |
| Andrew Chung, DO | Faculty | Nothing to disclose - 08/29/2024 |
| YONGSANG KIM, MD | Faculty, Other Planning Committee Member | Nothing to disclose - 10/10/2024 |
| Jisoo Ha, MD | Faculty | Nothing to disclose - 09/01/2024 |
| DAE-JUNG CHOI, MD, PhD | Faculty | Advisor-MaxMore|Advisor-Medinus|Advisor-Solendos - 10/03/2024 |
| Man Kyu Park, MD | Faculty | Nothing to disclose - 10/27/2024 |
| Yong Kim, MD | Faculty | Nothing to disclose - 09/06/2024 |
| Dong Hwa Heo, MD, PhD | Faculty, Other Planning Committee Member | Nothing to disclose - 09/10/2024 |
| Daniel Park, MD | Faculty, Planning Commitee Member | Consulting Fee-Stryker (Any division)|Consulting Fee-Orthofix|Consulting Fee-Arthrex|Consulting Fee-Medynus - 09/20/2024 |
| Ki-Eun Chang, MD | Faculty | Nothing to disclose - 09/21/2024 |
| Cheol Wung Park, MD, PhD | Faculty | Nothing to disclose - 11/07/2024 |
| Jang Yoon, MD, Assistant Professor of Neurosurgery | Faculty | Consulting Fee-Johnson & Johnson|Grant or research support-Johnson & Johnson|Consulting Fee-Amplify|Consulting Fee-RIWOspine|Consulting Fee-TrackX|Royalties or Patent Beneficiary-Kinesiometrics|Royalties or Patent Beneficiary-MedCyclops|Consulting Fee-Medyssey - 11/07/2024 |
| Brian Kwon, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-AMplify Surgical|Royalties or Patent Beneficiary-Globus Medical, Inc.|Consulting Fee-Arthrex|Consulting Fee-Medtronic (Any division) - 12/08/2024 |
| Philip K. Louie, MD | Faculty | Consulting Fee-Alphatec|Consulting Fee-Johnson & Johnson|Consulting Fee-Globus Medical, Inc.|Consulting Fee-Augmedics - 11/26/2024 |

**Agenda**

**[INSERT AGENDA HERE MANUALLY]**

**Acknowledgement of Commercial Support**

No commercial support has been received for this activity.